★ America V2AuditLine ALPHA

AuditLine › HHS OIG › Centers for Medicare and Medicaid Services

HHS OIG recommendation 23-E-02-028.03

CMS should take steps to inform providers about the availability of buprenorphine combination products in Part D, which can minimize the risk of…

Closed ImplementedThe publisher's status, as reported by HHS Office of Inspector General in the file read .

The recommendation, in the publisher's words

CMS should take steps to inform providers about the availability of buprenorphine combination products in Part D, which can minimize the risk of misuse and diversion.
Responsible agency
Centers for Medicare and Medicaid Services
Issued
May 16, 2023
Report
The Risk of Misuse and Diversion of Buprenorphine for Opioid Use Disorder Appears to Be Low in Medicare Part D (OEI-02-22-00160) · find it at HHS OIG
Kind of report
Evaluation
Agency response
Concur (as recorded by the publisher)
Closed
May 15, 2024 (publisher's date)
Publisher topics
Prescription Drug, Public Health Issues, Substance Abuse Disorder

“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.

Dated history

  1. Issued by HHS OIG. (publisher's date)
  2. Closed, with status “Closed Implemented”. (publisher's date)
  3. First recorded by AuditLine. (start of AuditLine's own history for this record)

Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.

Other recommendations from this report

3 more, of which 1 is open in the publisher's file.

Source

Open this report in HHS OIG's tracker This publisher's records (CSV)

Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows, SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.